At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We aspire to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality. Powered by data science and digital technologies, we drive solutions to advance research, clinical care, and patient empowerment. We believe that now, more than ever, biology and technology should go hand-in-hand to better meet patient needs, while enabling a shift towards more prevention-focused, affordable, and equitable care.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Neurological diseases are the leading cause of disability and the second-leading cause of death worldwide. We are advancing scientific innovation that takes us deep into the body’s nervous system with the potential to deliver new treatments that transform the lives of those who suffer from neurological and neurodegenerative disorders.
We now have 10 programs either in Phase 3 or filed with regulatory agencies, including in Alzheimer’s disease, neuropsychiatry, amyotrophic lateral sclerosis (ALS) and ophthalmology. We aim to further expand our multi-franchise portfolio by leveraging the interconnectivity in neuroscience.
Laurent Martarello, Head of Biogen’s Research and Early Development Imaging group, helps to monitor ASO (antisense oligonucleotide) delivery and whether it leads to clinical benefits for patients.
Innovating for Patients
Neurological diseases can affect every aspect of a patient’s life. Memory and cognition can deteriorate, and so can a person’s ability to speak, control their movements, or move at all. Biogen works fearlessly to innovate and find solutions to help address these challenges, grounded in the perspective of patients and caregivers. In 2020 we hosted multiple patient advocacy roundtables, furthering our commitment to early, ongoing and systematic patient involvement across each therapeutic area and within our investigational clinical settings.
Collaborating with MIT to Find Faster, More Efficient Processes
Biogen became one of the first contributors to Massachusetts Institute of Technology’s (MIT) collaboration, The AltHost Consortium, in 2020. AltHost, composed of leading organizations in biopharmaceuticals and vaccines, works to advance the speed and productivity of alternative host cell research and manufacturing. By sharing knowledge, practices and efficiencies, AltHost members explore innovative ways to produce biologics and vaccines for clinical usage in diseases from diabetes to cancer. For patients and healthcare systems, this holds potential for improved access, a more nimble and scalable manufacturing process and lower costs.
Building Depth in Our Pipeline
Few other areas hold as much need or as much promise for medical breakthroughs as neuroscience. Our success in multiple sclerosis (MS) gives our researchers insight into other disease areas, such as neuroprotection and axonal health, with potential applications in Alzheimer's disease, Parkinson’s disease, ALS, stroke and pain.
We believe that the emergence of promising modalities, including antisense oligonucleotide (ASOs) and gene therapy and advancements in biologics and small molecules, are opening new target spaces for potential therapeutic interventions. Our pursuit of multiple modalities may have the ability to prevent, halt or cure the progression of neurological diseases.
We continuously engage with external researchers in a number of therapeutic areas, including specialty medicines and rare diseases.
Advancing Our Portfolio
We are proud of our work to develop and expand our multi-franchise portfolio and deliver on our core business areas of MS and spinal muscular atrophy (SMA). Our hope is to improve patient health by offering therapies that may slow, halt or cure the progression of neurological and neurodegenerative diseases.
Determined to make a meaningful difference, we work fearlessly to find potential disease-modifying therapies in complex areas that urgently need them. In 2020 we added or advanced 12 clinical programs, bolstering our early- and late-stage pipeline. We also continued to invest in internal capabilities and external collaborations that provide us with access to emerging science and cutting-edge platform technologies. We believe we are well positioned for growth with readouts from seven clinical programs expected in 2021, of which four are pivotal readouts.
Biogen is committed to the safety of our patients and the safe use of our products in all countries we serve. We support patients by monitoring the safety of Biogen investigational and marketed products, over the lifecycle of the products, through the science of Pharmacovigilance (PV).
We are also committed to the safe and ethical use of biotechnology to improve the quality of human life, and we recognize that all biotechnology companies must approach this continually advancing technology with a balance of vigilance, diligence and humility.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.